CN103520401B - A kind of Traditional Chinese medicine health-preserving preparation with auxiliary lipid-lowering function - Google Patents
A kind of Traditional Chinese medicine health-preserving preparation with auxiliary lipid-lowering function Download PDFInfo
- Publication number
- CN103520401B CN103520401B CN201310493268.9A CN201310493268A CN103520401B CN 103520401 B CN103520401 B CN 103520401B CN 201310493268 A CN201310493268 A CN 201310493268A CN 103520401 B CN103520401 B CN 103520401B
- Authority
- CN
- China
- Prior art keywords
- extract
- atractylodis macrocephalae
- chinese medicine
- rhizoma atractylodis
- rhizoma alismatis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of Traditional Chinese medicine health-preserving preparation with auxiliary lipid-lowering function.This Traditional Chinese medicine health-preserving preparation is made up of the crude drug of following part by weight: Monas cuspurpureus Went 40-60, Rhizoma Alismatis extract 15-35, Rhizoma Atractylodis Macrocephalae extract 10-30, yeast rich in selenium 1-10.This Traditional Chinese medicine health-preserving preparation medicine assortment class is few, consumption proportion is precise and appropriate, has mutual Synergistic, auxiliary lipid-lowering function is remarkable.Said preparation bases oneself upon the rule for the treatment of of Chinese medicine to blood fat reducing, by replenishing QI to invigorate the spleen, eliminating phlegm and removing dampness, the turbid blood fat reducing of change, reaches the function of auxiliary antilipemic.Wherein, Monas cuspurpureus Went has blood circulation promoting and blood stasis dispelling, strengthening the spleen to promote digestion effect, and it is remarkable that modern study shows that it reduces cholesterol effect, and have the effect reducing triglyceride and low density lipoprotein, LDL and high density lipoprotein increasing; Rhizoma Alismatis, the Rhizoma Atractylodis Macrocephalae come from the classics side that the Eastern Han Dynasty cures holy Zhang Zhongjing " Medical Treasures of the Golden Chamber ", invigorating the spleen for eliminating dampness, change turbid blood fat reducing; Yeast rich in selenium is the sealing compound of cardiovascular and cerebrovascular vessel; Four medicine Synergistics, specimen is with executing, and auxiliary lipid-lowering function is remarkable.Meanwhile, the conbined usage of Monas cuspurpureus Went and yeast rich in selenium, the conbined usage of Rhizoma Alismatis and the Rhizoma Atractylodis Macrocephalae, makes said preparation also have the effect of the liver protecting (alcoholic fatty liver) and fat-reducing.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation, particularly there is the Traditional Chinese medicine health-preserving preparation of auxiliary lipid-lowering function.
Background technology
Along with dietary structure and lifestyle change, from the eighties in last century middle and late stage, the people suffering from hyperlipidemia in China urbanite is many, and age of onset is in the trend of becoming younger.Data according to modern medicine diseases monitoring show, more than nearly 3600 people of cardiovascular and cerebrovascular disease death toll that whole world every day causes because of hyperlipidemia, heart infarction, cerebral infarction, apoplexy, hemiplegia that China causes because of hyperlipidemia every year, disable, lethal number rises with the speed of average annual growth 12%.More severely fearful be; in the patient of China's hyperlipidemia exception, there is the patient reaching 80% not understand grave danger that hyperlipidemia causes to the health of people; in investigation, find that the heart infarction patient of 50% is prevented; in most cardiac, 80% is asymptomatic quiet person, and the cardiac of 86% just has the risk factor of blood fat, dysarteriotony to exist at morbidity previous decade.In fact hyperlipidemia has now become the first stealthy killer engulfing human health.Because of not enough to its understanding, and do not carry out active and effective prophylactic treatment, it is very serious that result makes PD arrive, until the consequence that can not save.Therefore prevention and early treatment are the keys alleviating this present situation early, and the present various medicine about blood fat reducing and functional food emerge in an endless stream, but real curative effect allows of no optimist, and market demand has the product for the treatment of both the principal and secondary aspects of a disease.
The pathogenic factor of hyperlipemia, mainly contains following several respects:
(1) along with the raising of people's living standard, there is quite a few people (particularly middle-aged and elderly people, quite a few teenager existing now) take in too much to saccharide, lipid material, lack physical training again simultaneously, lipid material is caused to store up too much in vivo, i.e. the usual obesity said of people; (2) metabolic disease: the diseases such as diabetes, hypothyroidism, hepatorenal disease cause lipid material metabolism bad, cause lipid material in blood to store up too much; (3) long-term smoking, alcoholic; The people getting used to sitting quietly, live irregular, emotion is emotional, spiritual in tension person; The crowds such as postmenopausal women, very easily cause lipid material metabolism disorder, cause lipid material in blood to store up too much; (4) hyperlipidemia family medical history person is had; (5) hypertensive patient is under hyperlipidaemic conditions, and because blood viscosity is high, velocity of blood flow is slow, very easily increases the weight of the symptom of hypertensive patient; Under hypertension, the deposition of blood fat in blood vessel wall can be increased the weight of again simultaneously.
With regard to theory of Chinese medical science, the main pathogenesis of hyperlipemia is the card of deficiency in origin and excess in superficiality, dysfunction of the spleen in transportation, endogenous damp formation, and blood stasis of holding concurrently for a long time, therefore should with invigorating the spleen for eliminating dampness, the turbid descending blood stasis dispelling for base therapy principle.Clinical practices a large amount of for a long time shows, it is little that Chinese medicine hyperlipemia has side effect, eutherapeutic good advantage.
The report of current Chinese medicine hyperlipemia is more, and for different etiology and pathogenesis, dialectical difference, prescription is also different.Patent CN200310110995 discloses a kind of pharmaceutical composition with regulating blood lipid action, and it is the medicament being raw material being made by Fructus Crataegi 4 parts, the Rhizoma Atractylodis Macrocephalae 3 parts, Rhizoma Alismatis 3 parts, 2 parts, Monas cuspurpureus Went.Patent CN200510049103 discloses a kind of Chinese patent medicine or health-care food composition, and said composition contains Monas cuspurpureus Went, soybean isoflavone, Rhizoma Alismatis, is also furnished with the one in Fructus Crataegi, Semen Cassiae or two kinds simultaneously.Patent CN200810104422 discloses a kind of pharmaceutical composition for the treatment of diabetes and/or hyperlipemia, and it is made up of the Radix Astragali, Folium Mori, Radix Puerariae, Rhizoma Alismatis, Monas cuspurpureus Went.Patent CN200910236322 discloses a kind of compositions with auxiliary lipid-lowering function, and Monas cuspurpureus Went, Folium Ginkgo extract, Radix Polygoni Multiflori Preparata extract, Rhizoma Alismatis extract sieve by respectively, mixing, tabletting.Patent CN201110136668 discloses a kind of pharmaceutical composition with auxiliary lipid-lowering function, and it, by Monas cuspurpureus Went, Rhizoma Alismatis extract, tea polyphenols, Fructus Crataegi extract, Folium Ginkgo extract mixing, adds adjuvant, make tablet, capsule, granule etc.
But how more reasonably to use Chinese medical theory, find the striving direction that medical material kind is few, consumption proportion is precise and appropriate, mutual Synergistic, prescription evident in efficacy are current work of Chinese medicine persons.
Monas cuspurpureus Went (Monascus-fermentedriceorredyeastrice) take rice as raw material, to ferment the aubergine rice-koji made through monascus (Monascus).This product is warm in nature, sweet in the mouth, has effect of blood circulation promoting and blood stasis dispelling, strengthening the spleen to promote digestion.The medical value of Monas cuspurpureus Went is described: " help digestion invigorate blood circulation, the dry stomach of spleen invigorating, control water paddy under dysentery with red and white feces " in Compendium of Material Medica.Teach from Japanese Endo and filtered out potent component for reducing blood fat acid lovastatin (MonacolinK) in 1979 in tunning at aspergillus terreus and red monascus, and be developed as the atorvastatin for the treatment of hypercholesterolemia by the U.S. after, the health care curative effect of Monas cuspurpureus Went and disease cure function are just causing the very big concern of Chinese scholars, MonacolinK and analog thereof are the specific inhibitors of body inner cholesterol synzyme HMG-CoA reductase, it is remarkable to serum cholesterol reducing effect, and have the effect reducing triglyceride and low-density lipoprotein cholesterol and high density lipoprotein increasing cholesterol.Further research finds in Monas cuspurpureus Went except containing except Monacolin compounds, also containing the biological active substances that Ergota street alcohol, biological flavone, soap former times, dietary fiber, aminopolysaccharide etc. are abundant, there is the pharmacological actions widely such as blood fat reducing, blood pressure lowering, blood sugar lowering, antitumor, resisting fatigue, enhancing immunity.
Rhizoma Alismatis (Alismaorientalis (Sam.) Juzep) is Notes On Alism At Aceae, and its dry tuber is one of the most frequently used Chinese crude drug, for dysuria, edema distension, have loose bowels, oliguria, phlegm retention, the disease such as dizzy, the puckery pain of pyretic stranguria.Clinical application research in recent years shows, except having obvious diuresis, Rhizoma Alismatis and extract thereof also may have blood pressure lowering to a certain degree, anti-fatty liver, blood fat reducing and study of anti-atherogenic effect.
The Rhizoma Atractylodis Macrocephalae begins to be loaded in Shennong's Herbal, and being classified as top grade, is the dry rhizome of feverfew Rhizoma Atractylodis Macrocephalae AractyodesmacrocephalaKoidz., and having the effect that invigorating the spleen and benefiting QI, dampness diuretic, hidroschesis are antiabortive, is traditional Chinese medical science spleen reinforcing key medicine.Modern pharmacology research shows that the Rhizoma Atractylodis Macrocephalae has immunomodulating, diuresis, antitumor, the anti-ageing effect of waiting for a long time, and its compatibility compound recipe has as the fat side that disappears, ZEXIE TANG and the beneficial heart lead to Tang Dengjun the effect regulating hyperlipemia.
ZEXIE TANG comes from the Eastern Han Dynasty to cure the inner classical proved recipe of holy Zhang Zhongjing " Medical Treasures of the Golden Chamber ", and this prescription is made up of Rhizoma Alismatis, the Rhizoma Atractylodis Macrocephalae two Chinese crude drug compatibilities, and the effect of Rhizoma Alismatis focuses on that diuretic is descending, damp eliminating effect, and the drink stopped can be made to go from urine; The effect of the Rhizoma Atractylodis Macrocephalae then focuses on spleen invigorating controlling the water circulation effect, water can be made to wet and both change and do not gather again.The party is used for the treatment of the earliest and emits dusk dizzy, is also used for the treatment of hyperlipemia afterwards, and through long-term clinical verification, proves that the party has good effect for reducing blood fat.
Selenium is the necessary trace element of human body, has very important physiological function, closely related with the health of the mankind.Selenium can prevention and prohibition tumor, defying age, maintenance cardiovascular system normal function, prevention of arterial sclerosis and the appearance of coronary heart disease.Yeast rich in selenium is exactly add selenium element in the process of culture yeasts, selenium has been absorbed during yeast growth, the protein of selenium in yeast body and polysaccharide organic are combined and are converted into biological selenium, thus eliminate chemical selenium (as sodium selenite) toxicity of human body and the intestines and stomach are stimulated, selenium more efficiently, is more safely absorbed by the body utilization.
Summary of the invention
For reaching above object, there is provided that a kind of medical material kind is few, consumption proportion is precise and appropriate, there is mutual Synergistic, the significant Traditional Chinese medicine health-preserving preparation of auxiliary lipid-lowering function, we according to motherland's medical science to the understanding of hyperlipidaemic conditions and Therapeutic Principle, base oneself upon Chinese medicine by invigorating the spleen for eliminating dampness, the turbid descending blood stasis dispelling treatment hyperlipidemia basic principle, with reference to modern pharmacological research achievement and former various proved recipes, grain is gone to get essence, four Chinese medicine is eaten the raw material of homology, rigorous compatibility, is prepared into a kind of Traditional Chinese medicine health-preserving preparation of auxiliary lipid-lowering function.Meanwhile, said preparation also has the effect of the liver protecting (alcoholic fatty liver) and fat-reducing.
This Traditional Chinese medicine health-preserving preparation is made up of the crude drug of following part by weight: Monas cuspurpureus Went 40-60, Rhizoma Alismatis extract 15-35, Rhizoma Atractylodis Macrocephalae extract 10-30, yeast rich in selenium 1-10.
Wherein, the preparation technology of Rhizoma Alismatis extract is: Rhizoma Alismatis decoction pieces adds 8 times amount soak by water 2 times, each 1.5h, filters, and merges; Under vacuum is-0.08 ~-0.06Mpa condition, being evaporated to relative density is that 1.2 ~ 1.25 (60 DEG C measure) obtain thick extractum; Thick extractum carries out vacuum drying and pulverizes, i.e. Rhizoma Alismatis extract.The preparation technology of Rhizoma Atractylodis Macrocephalae extract is: Rhizoma Atractylodis Macrocephalae decoction pieces adds 8 times amount soak by water 2 times, each 1.5h, filters and merges; Under vacuum is-0.08 ~-0.06Mpa condition, being evaporated to relative density is that 1.2 ~ 1.25 (60 DEG C measure) obtain thick extractum; Thick extractum carries out vacuum drying and pulverizes, i.e. Rhizoma Atractylodis Macrocephalae extract.
Preferred: Monas cuspurpureus Went 45-55, Rhizoma Alismatis extract 20-30, Rhizoma Atractylodis Macrocephalae extract 15-25, yeast rich in selenium 3-8.
Further preferably: Monas cuspurpureus Went 50, Rhizoma Alismatis extract 25, Rhizoma Atractylodis Macrocephalae extract 20, yeast rich in selenium 5.
The preparation method of above-mentioned Traditional Chinese medicine health-preserving preparation comprises the following steps:
(1) take Monas cuspurpureus Went and yeast rich in selenium difference, cross 60 mesh sieves mixing, obtain mixed-powder;
(2) take by weight proportion and mix the mixed-powder of step (1) gained and Rhizoma Alismatis extract and Rhizoma Atractylodis Macrocephalae extract, being prepared into pharmaceutically acceptable preparation.
In invention formulation, described Traditional Chinese medicine health-preserving preparation is capsule, tablet, granule, powder or oral liquid, for enabling above-mentioned dosage form realize, can add the acceptable adjuvant of pharmacy when preparing these dosage forms, such as: filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic etc., filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc., disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc., lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc., suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc., binding agent comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc., sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc., correctives comprises: sweeting agent and various essence, and antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, acetic acid chloroethene is fixed, Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods.
Present invention also offers above-mentioned Traditional Chinese medicine health-preserving preparation and prepare the application in blood lipid-lowering medicine.
Containing Monas cuspurpureus Went, Rhizoma Alismatis extract, Rhizoma Atractylodis Macrocephalae extract, yeast rich in selenium four taste raw material in this Traditional Chinese medicine health-preserving preparation.Said preparation bases oneself upon the rule for the treatment of of Chinese medicine to blood fat reducing, by replenishing QI to invigorate the spleen, eliminating phlegm and removing dampness, the turbid blood fat reducing of change, reaches the function of auxiliary antilipemic.Monas cuspurpureus Went has blood circulation promoting and blood stasis dispelling, strengthening the spleen to promote digestion effect, and it is remarkable that modern study shows that it reduces cholesterol effect, and have the effect reducing triglyceride and low density lipoprotein, LDL and high density lipoprotein increasing; Rhizoma Alismatis, the Rhizoma Atractylodis Macrocephalae come from the classics side that the Eastern Han Dynasty cures holy Zhang Zhongjing " Medical Treasures of the Golden Chamber ", invigorating the spleen for eliminating dampness, change turbid blood fat reducing; Yeast rich in selenium is the sealing compound of cardiovascular and cerebrovascular vessel; Mutual use worked in coordination with by four medicines, and specimen is with executing, and replenishing QI to invigorate the spleen, eliminating phlegm and removing dampness, the turbid blood fat reducing of change, prove to have the health care of auxiliary antilipemic through human experiment and animal function test.Meanwhile, the conbined usage of Monas cuspurpureus Went and yeast rich in selenium, the conbined usage of Rhizoma Alismatis and the Rhizoma Atractylodis Macrocephalae, makes said preparation also have the effect of the liver protecting (alcoholic fatty liver) and fat-reducing.
Detailed description of the invention
Embodiment 1
The weight of each crude drug is: Monas cuspurpureus Went 50g, Rhizoma Alismatis extract 25g, Rhizoma Atractylodis Macrocephalae extract 20g, yeast rich in selenium 5g.
Preparation method is:
(1) take Monas cuspurpureus Went and yeast rich in selenium difference, cross 60 mesh sieves mixing, obtain mixed-powder;
(2) take by weight proportion and mix the mixed-powder of step (1) gained and Rhizoma Alismatis extract and Rhizoma Atractylodis Macrocephalae extract, adding appropriate amount of starch, fully mix after sieving, be distributed in capsule and get final product, every 0.35g.
Embodiment 2
The weight of each crude drug is: Monas cuspurpureus Went 45g, Rhizoma Alismatis extract 20g, Rhizoma Atractylodis Macrocephalae extract 25g, yeast rich in selenium 3g.
Preparation method is:
(1) take Monas cuspurpureus Went and yeast rich in selenium difference, cross 60 mesh sieves mixing, obtain mixed-powder;
(2) take by weight proportion and mix the mixed-powder of step (1) gained and Rhizoma Alismatis extract and Rhizoma Atractylodis Macrocephalae extract, use appropriate distilled water diluting, add appropriate polyvinylpyrrolidone, filter, diluent is 20% containing crude drug amount, add simple syrup, potassium sorbate, obtained oral liquid.
Embodiment 3
The weight of each crude drug is: Monas cuspurpureus Went 55g, Rhizoma Alismatis extract 30g, Rhizoma Atractylodis Macrocephalae extract 15g, yeast rich in selenium 8g.
Preparation method is:
(1) take Monas cuspurpureus Went and yeast rich in selenium difference, cross 60 mesh sieves mixing, obtain mixed-powder;
(2) take by weight proportion and mix the mixed-powder of step (1) gained and Rhizoma Alismatis extract and Rhizoma Atractylodis Macrocephalae extract, then mixing with appropriate amount of starch, sucrose, adding 30mL anhydrous alcohol for medical use, stir, make soft material; Soft material is added in the oscillating granulator that 14 eye mesh screens are housed, makes wet granular, in heated-air circulation oven, dry granulate for 50 DEG C; Add magnesium stearate 5g mixing, direct compression and get final product, every sheet 0.35g after sieving.
Embodiment 4
The weight of each crude drug is: Monas cuspurpureus Went 40g, Rhizoma Alismatis extract 15g, Rhizoma Atractylodis Macrocephalae extract 30g, yeast rich in selenium 1g.
Preparation method is:
(1) take Monas cuspurpureus Went and yeast rich in selenium difference, cross 60 mesh sieves mixing, obtain mixed-powder;
(2) take by weight proportion and mix the mixed-powder of step (1) gained and Rhizoma Alismatis extract and Rhizoma Atractylodis Macrocephalae extract, then mixing with appropriate lactose, microcrystalline Cellulose, adding 30mL anhydrous alcohol for medical use, stir, make soft material; Soft material is added in the oscillating granulator that 14 eye mesh screens are housed, makes wet granular, in heated-air circulation oven, dry granulate for 50 DEG C; Add magnesium stearate 5g mixing, direct compression and get final product, every sheet 0.35g after sieving.
Embodiment 5
The weight of each crude drug is: Monas cuspurpureus Went 60g, Rhizoma Alismatis extract 35g, Rhizoma Atractylodis Macrocephalae extract 10g, yeast rich in selenium 10g.
Preparation method is:
(1) take Monas cuspurpureus Went and yeast rich in selenium difference, cross 60 mesh sieves mixing, obtain mixed-powder;
(2) take by weight proportion and mix the mixed-powder of step (1) gained and Rhizoma Alismatis extract and Rhizoma Atractylodis Macrocephalae extract, then mixing with appropriate lactose, microcrystalline Cellulose, adding 30mL anhydrous alcohol for medical use, stir, make soft material; Soft material is added in the oscillating granulator that 14 eye mesh screens are housed, makes wet granular, in heated-air circulation oven, dry granulate for 50 DEG C, add magnesium stearate 5g mixing, use composite film packaging, inspection, obtain granular pattern electuary.
Embodiment 6
The weight of each crude drug is: Monas cuspurpureus Went 50g, Rhizoma Alismatis extract 25g, Rhizoma Atractylodis Macrocephalae extract 20g, yeast rich in selenium 5g.
Preparation method is:
(1) take Monas cuspurpureus Went and yeast rich in selenium difference, cross 60 mesh sieves mixing, obtain mixed-powder;
(2) take by weight proportion and mix the mixed-powder of step (1) gained and Rhizoma Alismatis extract and Rhizoma Atractylodis Macrocephalae extract, then mixing with appropriate amount of starch, sucrose, adding 30mL anhydrous alcohol for medical use, stir, make soft material; Soft material is added in the oscillating granulator that 14 eye mesh screens are housed, makes wet granular, in heated-air circulation oven, dry granulate for 50 DEG C; Add magnesium stearate 5g mixing, fill capsule, every 0.35g.
Embodiment 7
The weight of each crude drug is: Monas cuspurpureus Went 48g, Rhizoma Alismatis extract 20g, Rhizoma Atractylodis Macrocephalae extract 25g, yeast rich in selenium 3g.
Preparation method is:
(1) take Monas cuspurpureus Went and yeast rich in selenium difference, cross 60 mesh sieves mixing, obtain mixed-powder;
(2) take by weight proportion and mix the mixed-powder of step (1) gained and Rhizoma Alismatis extract and Rhizoma Atractylodis Macrocephalae extract, the soybean oil joining 70 DEG C dissolves, add ethyl cellulose again, fully mix with helical mixer, cross colloid mill, degassed, pelleting, sizing are dry, row coils drying, select ball polishing, obtained soft capsule, every 0.35g.
Embodiment 8
The weight of each crude drug is: Monas cuspurpureus Went 53g, Rhizoma Alismatis extract 30g, Rhizoma Atractylodis Macrocephalae extract 15g, yeast rich in selenium 8g.
Preparation method is:
(1) take Monas cuspurpureus Went and yeast rich in selenium difference, cross 60 mesh sieves mixing, obtain mixed-powder;
(2) take by weight proportion and mix the mixed-powder of step (1) gained and Rhizoma Alismatis extract and Rhizoma Atractylodis Macrocephalae extract, then mixing with appropriate amount of starch, adding 30mL anhydrous alcohol for medical use, stir, make soft material; Soft material is added in the oscillating granulator that 14 eye mesh screens are housed, makes wet granular, in heated-air circulation oven, dry granulate for 50 DEG C; Add magnesium stearate 5g mixing, direct compression and get final product, every sheet 0.35g after sieving.
Test example 1 Report on Animal
Sample: capsule prepared by embodiment 6,0.35 gram every.
Laboratory animal: the SPF level SD kind male white rat of being bred by Guangdong Medical Lab Animal Center, body weight 180-220g; Animal housing temperature 22-25 DEG C, relative humidity 55-75%.
Dosage choice and animal subject give mode: inventive samples establishes 175,350, a 700mg/kgBW3 dosage group (5,10,20 times that are equivalent to that human body recommends consumption respectively, be respectively low dose group, middle dosage group, high dose group), establish the matched group (normal control of a normal feedstuff matched group (Basal control), a hyperlipidemia model matched group (high fat contrast) and patent CN200310110995 embodiment 1 again, dosage is 700mg/kgBW), often organize 10 animals.Basic, normal, high dosage group and normal control group get capsule 3.5g, 7.0g, 14.0g and 14.0g respectively, respectively add pure water to 200mL, mixing, is made into 17.5,35.0,70.0 and 70.0mg/mL strength solution, give corresponding dosage treated animal gavage, gavage amount is 1.0mL/100gBW; Basal control group and model control group give isopyknic pure water, every day gavage once, continuous 30 days.
Key instrument and reagent: OLYMPUSAU400 type automatic biochemistry analyzer, centrifuge, swirl mixing device, constant water bath box; T-CHOL (TC), triglyceride (TG), HDL-C (HDL-C) test kit.
Experimental technique: according to the auxiliary lipid-lowering function method of inspection in " health food inspection and assessment technical specification " (version in 2003), employing hyperlipoidemia method-preventative to given the test agent.Rat observes 5 days at the indoor feed normal feedstuff of cleaning grade zoopery, adjoins blood sampling measure every observation index normal value after fasting 16h from the ophthalmic of rat.According to TC level, adopt stratified random sampling method that rat is divided into 6 groups, often organize 10, and suitably adjustment makes TG, HDL-C of each group of rat and original body mass balanced as far as possible.After starting experiment, except normal feedstuff matched group, all use high lipid food feed for all the other each group, basic, normal, high dosage group and normal control group rat oral gavage give test solution simultaneously, and Basal control group and high fat matched group gavage give pure water.Weigh once weekly, and according to body weight adjustment gavage amount.Test and measure serum TC, TG, HDL-C content to blood sampling in the 31st day, take a blood sample front animal fasting 16h.The mensuration of serum TC, TG, HDL-C content all uses enzyme reagent-end-point method.
Data Processing in Experiment: adopt SPSS statistical software to carry out variance analysis statistical disposition.
Result judges: in serum total cholesterol, triglyceride, HDL-C three indexs, and serum total cholesterol and the triglyceride binomial index positive, can judge that the zoopery of given the test agent auxiliary antilipemic is positive.
Experimental result:
1. inventive samples is on the impact of rat body weight
The results are shown in Table 1.Before experiment, the body weight of each group rat is more balanced, no significant difference between group.Experiment was to the 30th day, and body weight and the gain in weight of high fat control rats are greater than Basal control group, and the difference of two groups has significance (P<0.05); The body weight of basic, normal, high Three doses group and normal control group rat is less than high fat matched group, but the body weight of each group rat and gain in weight compare with high fat matched group that there are no significant difference (P>0.05).Show that sample of the present invention increases the body weight of the rat of high lipid food feed to have no significant effect.
The body weight change (means standard deviation) of table 1 each group rat before and after testing
2. inventive samples is on the impact of serum total cholesterol (TC) content
The results are shown in Table 2.Before and after experiment, the serum TC content of each group rat is basically identical, the no significant difference (P>0.05) between each group.Experiment was to the 30th day, and high fat matched group TC content is higher than Basal control group, and difference has very significant (P<0.01), shows that hyperlipidemia model is set up.Experiment was to the 30th day, the TC of low dose group and normal control group rat is all lower than high fat matched group, and the difference of middle dosage group, high dose group and high fat matched group has significance (respectively P<0.05 and P<0.01).Show that sample of the present invention has the effect of the serum total cholesterol content of the rat reducing high lipid food feed.
Table 2 is respectively organized before rat experiment and the 30th day TC content (means standard deviation)
3. inventive samples is on the impact of serum triglycerides (TG) content
The results are shown in Table 3.Before and after experiment, the serum TG content of each group rat is basically identical, the no significant difference (P>0.05) between each group.Experiment was to the 30th day, and high fat matched group TC content is higher than Basal control group, and difference has very significant (P<0.01), shows that hyperlipidemia model is set up.Experiment was to the 30th day, the TC of low dose group and normal control group rat is all lower than high fat matched group, and the difference of middle dosage group, high dose group and high fat matched group has significance (respectively P<0.05 and P<0.01).Show that sample of the present invention has the effect of the serum triglycerides content of the rat reducing high lipid food feed.
Table 3 is respectively organized before rat experiment and the 30th day TG content (means standard deviation)
4. inventive samples is on the impact of serum High Density Lipoprotein Cholesterol (HDL-C) content
The results are shown in Table 4.Before and after experiment, the serum HDL-C level of each group rat is basically identical, the no significant difference (P>0.05) between each group.Experiment was to the 30th day, and the HDL-C content of low dose group, middle dosage group, high dose group and normal control group rat compares with high fat matched group, and there are no significant for difference (P>0.05).Show that the serum High Density Lipoprotein Cholesterol content of sample of the present invention on the rat of high lipid food feed is without obvious impact.
Table 4 is respectively organized before rat experiment and the 30th day HDL-C content (means standard deviation)
5. result judges
Respectively with 175,350, the inventive samples of 700mg/kgBW (be equivalent to respectively 5,10,20 times that human body recommends consumption) dosage is to the continuous gavage of the rat of high lipid food feed 30 days, serum total cholesterol (TC) and triglyceride (TG) content of rat can be reduced, on serum High Density Lipoprotein Cholesterol (HDL-C) content of rat without obvious impact, sample of the present invention is pointed out to have auxiliary lipid-lowering function.There is the significant difference on statistical significance simultaneously compared with normal control group, after proving crude drug of the present invention combination, create synergism, there is unforeseeable technique effect.
Claims (6)
1. there is a Traditional Chinese medicine health-preserving preparation for auxiliary lipid-lowering function, it is characterized in that, be made up of the crude drug of following part by weight: Monas cuspurpureus Went 40-60, Rhizoma Alismatis extract 15-35, Rhizoma Atractylodis Macrocephalae extract 10-30, yeast rich in selenium 1-10; Wherein the preparation technology of Rhizoma Alismatis extract is: Rhizoma Alismatis decoction pieces adds 8 times amount soak by water 2 times, each 1.5h, filters, and merges; Under vacuum is-0.08 ~-0.06Mpa condition, when the relative density be evaporated at 60 DEG C is 1.2 ~ 1.25, obtain thick extractum; Thick extractum carries out vacuum drying and pulverizes, i.e. Rhizoma Alismatis extract; The preparation technology of Rhizoma Atractylodis Macrocephalae extract is: Rhizoma Atractylodis Macrocephalae decoction pieces adds 8 times amount soak by water 2 times, each 1.5h, filters and merges; Under vacuum is-0.08 ~-0.06Mpa condition, when the relative density be evaporated at 60 DEG C is 1.2 ~ 1.25, obtain thick extractum; Thick extractum carries out vacuum drying and pulverizes, i.e. Rhizoma Atractylodis Macrocephalae extract.
2. Traditional Chinese medicine health-preserving preparation according to claim 1, is characterized in that, is made up of the crude drug of following part by weight: Monas cuspurpureus Went 45-55, Rhizoma Alismatis extract 20-30, Rhizoma Atractylodis Macrocephalae extract 15-25, yeast rich in selenium 3-8.
3. Traditional Chinese medicine health-preserving preparation according to claim 1, is characterized in that, is made up of the crude drug of following part by weight: Monas cuspurpureus Went 50, Rhizoma Alismatis extract 25, Rhizoma Atractylodis Macrocephalae extract 20, yeast rich in selenium 5.
4. the Traditional Chinese medicine health-preserving preparation according to claim 1 or 3, is characterized in that, described Traditional Chinese medicine health-preserving preparation is capsule, tablet, granule, powder or oral liquid.
5. the preparation method of the Traditional Chinese medicine health-preserving preparation according to claim 1-3 any one, is characterized in that, comprise the following steps:
(1) take Chinese crude drug Monas cuspurpureus Went, Rhizoma Alismatis decoction pieces, Rhizoma Atractylodis Macrocephalae decoction pieces and yeast rich in selenium, clean;
(2) Monas cuspurpureus Went after cleaning and yeast rich in selenium are crossed 40 mesh sieves mixing respectively, obtain mixed-powder;
(3) Rhizoma Alismatis decoction pieces is added 8 times amount soak by water 2 times, each 1.5h, filter, merge; Under vacuum is-0.08 ~-0.06Mpa condition, be evaporated to 60 DEG C measure relative densities be 1.2 ~ 1.25 thick extractum; Thick extractum carries out vacuum drying and pulverizes, and obtains Rhizoma Alismatis extract; Rhizoma Atractylodis Macrocephalae decoction pieces is added 8 times amount soak by water 2 times, each 1.5h, filter and merge; Under vacuum is-0.08 ~-0.06Mpa condition, be evaporated to 60 DEG C measure relative densities be 1.2 ~ 1.25 thick extractum; Thick extractum carries out vacuum drying and pulverizes, and obtains Rhizoma Atractylodis Macrocephalae extract;
(4) take by weight proportion and mix the mixed-powder of step (2) gained and the Rhizoma Alismatis extract of step (3) gained and Rhizoma Atractylodis Macrocephalae extract, being prepared into pharmaceutically acceptable preparation.
6. the application in blood lipid-lowering medicine prepared by the Traditional Chinese medicine health-preserving preparation according to claim 1-4 any one.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310493268.9A CN103520401B (en) | 2013-10-21 | 2013-10-21 | A kind of Traditional Chinese medicine health-preserving preparation with auxiliary lipid-lowering function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310493268.9A CN103520401B (en) | 2013-10-21 | 2013-10-21 | A kind of Traditional Chinese medicine health-preserving preparation with auxiliary lipid-lowering function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103520401A CN103520401A (en) | 2014-01-22 |
| CN103520401B true CN103520401B (en) | 2016-03-02 |
Family
ID=49922988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310493268.9A Active CN103520401B (en) | 2013-10-21 | 2013-10-21 | A kind of Traditional Chinese medicine health-preserving preparation with auxiliary lipid-lowering function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103520401B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103385990B (en) * | 2013-08-13 | 2015-06-17 | 吴中区胥口精益生物医药研究所 | Rhizoma alismatis essence and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1618441A (en) * | 2003-11-21 | 2005-05-25 | 成都地奥制药集团有限公司 | Medicinal composition for regulating blood fat, prepn. method and use thereof |
| CN102106895A (en) * | 2009-12-28 | 2011-06-29 | 安琪酵母股份有限公司 | Composition with function of regulating blood fat |
-
2013
- 2013-10-21 CN CN201310493268.9A patent/CN103520401B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1618441A (en) * | 2003-11-21 | 2005-05-25 | 成都地奥制药集团有限公司 | Medicinal composition for regulating blood fat, prepn. method and use thereof |
| CN102106895A (en) * | 2009-12-28 | 2011-06-29 | 安琪酵母股份有限公司 | Composition with function of regulating blood fat |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103520401A (en) | 2014-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101658597A (en) | Health care step-down tea and preparation method thereof | |
| CN102579836B (en) | Traditional Chinese medical dendrobium huoshanense composition and preparation method thereof | |
| CN102551046B (en) | Natural health composition for weight reduction and application of same | |
| CN103006989B (en) | Medical composition for treating diabetic nephropathy | |
| CN107912773A (en) | A kind of preparation for being used to alleviate physical fatigue | |
| CN103520401B (en) | A kind of Traditional Chinese medicine health-preserving preparation with auxiliary lipid-lowering function | |
| CN103690819A (en) | Traditional Chinese medicinal composition capable of preventing and treating cardiovascular and cerebrovascular diseases and with weight reducing function | |
| CN104336596A (en) | Medicine composition capable of lowering blood lipid and preparation method thereof | |
| CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
| CN103735621B (en) | A kind of Chinese medicine composition with blood fat reducing and enhancing immunity effect | |
| CN102228551A (en) | Chinese medicinal composition for preventing and treating injury of gastric mucosa and preparation method thereof | |
| CN109771578A (en) | The composition for preventing and treating diabetes and complication | |
| CN101850039A (en) | Composition with auxiliary lipid-lowering function | |
| CN1063649C (en) | Red ginseng and hawthorn fruit health-care wine | |
| CN103272146B (en) | Medicine composition used for preventing and treating alcoholic fatty liver and preparation method thereof | |
| CN106177176B (en) | A kind of Halth-care composition and its preparation method and application | |
| CN1115159C (en) | Red sage containing medicine composition and its preparation and use | |
| CN106177227A (en) | A kind of compositions containing coenzyme Q10 strengthening body immunity | |
| CN101884760B (en) | Chinese medicinal composition for treating diabetes mellitus and preparation method thereof | |
| CN1660207A (en) | Preparation of health care for reducing blood fat and cholesterol, and producing method | |
| CN103223143B (en) | Traditional Chinese medicine composition for treating simple obesity, and preparation method and application thereof | |
| CN109528827B (en) | Pharmaceutical composition and preparation for promoting blood circulation, removing blood stasis and reducing blood fat and preparation method thereof | |
| CN103285110B (en) | Traditional Chinese medicine for treating hyperlipidemia and preparation method thereof | |
| CN109316565A (en) | A kind of blood-fat reducing composition and its preparation method and application | |
| CN103316106A (en) | Danshan fat reducing granules and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 101100, No. 2, building 58, 25 Xinhua West Street, Beijing, Tongzhou District, 2523 Applicant after: Huaxia Xianbao (Beijing) Traditional Chinese Medicine Research Institute Co., Ltd. Address before: 101121 Tongzhou District Cloud View Road Beijing City 706 Applicant before: Huaxia Xianbao (Beijing) Traditional Chinese Medicine Research Institute Co., Ltd. |
|
| COR | Change of bibliographic data | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |